PREFEREnce-based Randomized Evaluation of Treatment Modalities in Low or Early Intermediate-risk Prostate Cancer

The clinical trial PREFERE aims to recruit 7600 patients with “early intermediate” prostate cancer. The goal is to confirm noninferiority of cancer-specific survival after external-beam radiotherapy, permanent seed implantation, or active surveillance compared with radical prostatectomy.